U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic ArthritisBusiness Wire • 09/28/20
Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trialsPRNewsWire • 09/28/20
A Second Wave of Coronavirus Could Be Coming: 3 Stocks to Buy Before It HitsThe Motley Fool • 09/27/20
FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell LymphomaBusiness Wire • 09/23/20
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson DiseaseBusiness Wire • 09/23/20
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with AnalystsBusiness Wire • 09/22/20
OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and BinimetinibBusiness Wire • 09/21/20
3 Coronavirus Vaccines in Phase 3 Clinical Studies: How They Stack Up Against Each OtherThe Motley Fool • 09/18/20
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of MedicinePRNewsWire • 09/18/20